EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia

Mark E Layton iD, Jeffrey C Kern, Timothy J Hartingh, William D Shipe iD, Izzat Raheem iD, Monika Kandebo, Robert P Hayes, Sarah Huszar, Donnie Eddins, Bennett Ma, Joy Fuerst, Gordon K Wollenberg und 7 weitere

Journal of Medicinal Chemistry · 26.01.2023 · 66 (2) · 1157-1171

DOI: 10.1021/acs.jmedchem.2c01521 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 10.01.2023. Verfasst von Mark E Layton und 18 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States. Hauptthemen laut MEDLINE: Phosphodiesterase Inhibitors, Schizophrenia. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Merck Sharp and Dohme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PDE10A is an important regulator of striatal signaling that, when inhibited, can normalize dysfunctional activity. Given the involvement of dysfunctional striatal activity with schizophrenia, PDE10A inhibition represents a potentially novel means for its treatment. With the goal of developing PDE10A inhibitors, early optimization of a fragment hit through rational design led to a series of potent pyrimidine PDE10A inhibitors that required further improvements in physicochemical properties, off-target activities, and pharmacokinetics. Herein we describe the discovery of an isomeric pyrimidine series that addresses the liabilities seen with earlier compounds and resulted in the invention of compound 18 (MK-8189), which is currently in Phase 2b clinical development for the treatment of schizophrenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphodiesterase InhibitorsSchizophreniaHumansCrystallography, X-RayPhosphoric Diester HydrolasesPyrimidinesStructure-Activity RelationshipSulfur Compounds

Substanzen

Phosphodiesterase InhibitorsPhosphoric Diester HydrolasesPyrimidinesPDE10A protein, humanMK-8189Sulfur Compounds

Autor:innen und Institutionen

  • Discovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Neuroscience, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Structural Chemistry, Merck & Co., Inc., Boston, Massachusetts 02115, United States.
  • In Vivo Pharmacology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Pharmacokinetics, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Discovery Pharmaceutical Sciences, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.

ORCID-Profile: Mark E Layton, William D Shipe, Izzat Raheem, Georgia B McGaughey, Jason M Uslaner

Förderung

  • Merck Sharp and Dohme

Zitieren

APA

Layton, M. E., Kern, J. C., Hartingh, T. J., Shipe, W. D., Raheem, I., Kandebo, M., Hayes, R. P., Huszar, S., Eddins, D., Ma, B., Fuerst, J., Wollenberg, G. K., Li, J., Fritzen, J., McGaughey, G. B., Uslaner, J. M., Smith, S. M., Coleman, P. J., & Cox, C. D. (2023). Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia. Journal of Medicinal Chemistry, 66(2), 1157-1171. https://doi.org/10.1021/acs.jmedchem.2c01521

Vancouver

Layton ME, Kern JC, Hartingh TJ, Shipe WD, Raheem I, Kandebo M, et al. Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia. Journal of Medicinal Chemistry. 2023;66(2):1157-1171. doi:10.1021/acs.jmedchem.2c01521

BibTeX
@article{Layton2023,
  author = {Layton, Mark E and Kern, Jeffrey C and Hartingh, Timothy J and Shipe, William D and Raheem, Izzat and Kandebo, Monika and Hayes, Robert P and Huszar, Sarah and Eddins, Donnie and Ma, Bennett and Fuerst, Joy and Wollenberg, Gordon K and Li, Jing and Fritzen, Jeff and McGaughey, Georgia B and Uslaner, Jason M and Smith, Sean M and Coleman, Paul J and Cox, Christopher D},
  title = {Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {2},
  pages = {1157--1171},
  doi = {10.1021/acs.jmedchem.2c01521}
}
Kostenlos starten →